What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of venetoclax-based regimens in treating chronic lymphocytic leukemia in second and later lines of therapy.

December 8, 2025Blood

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers of slovakia

View Full Paper

Ask AI

Bookmark

Authors

JCJuraj Chudej EFEmília Flochová ĽVĽubica Váleková

Discussion

Member takes

Overview

Retrospective analysis shows venetoclax improves outcomes in CLL patients, indicating high efficacy and acceptable safety profile.

Key Points

This research aims to evaluate the efficacy and safety of venetoclax-based regimens in treating chronic lymphocytic leukemia in second and later lines of therapy.
Retrospective analysis of 98 CLL patients treated with venetoclax from 2018 to 2024.
Treatment assessed included monotherapy and combination with rituximab.
Response monitored via clinical evaluation, imaging, and laboratory parameters following iwCLL criteria.
Statistical analysis performed using descriptive statistics, Kaplan-Meier curves, and various tests.
Overall response rate was high at 67% with unconfirmed complete remission in 56% of prior ibrutinib patients.
Median progression-free survival was 46 months; median overall survival not reached, estimated at 52.5 months.
Hematologic adverse events reported in 64% of patients, non-hematologic in 42%, indicating manageable toxicity.

Cite This Study

Chudej et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d218 https://doi.org/10.1182/blood-2025-7424

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers of slovakia

View Full Paper

Ask AI

Bookmark

Authors

JCJuraj Chudej EFEmília Flochová ĽVĽubica Váleková

Discussion

Member takes

Overview

Retrospective analysis shows venetoclax improves outcomes in CLL patients, indicating high efficacy and acceptable safety profile.

Key Points

This research aims to evaluate the efficacy and safety of venetoclax-based regimens in treating chronic lymphocytic leukemia in second and later lines of therapy.
Retrospective analysis of 98 CLL patients treated with venetoclax from 2018 to 2024.
Treatment assessed included monotherapy and combination with rituximab.
Response monitored via clinical evaluation, imaging, and laboratory parameters following iwCLL criteria.
Statistical analysis performed using descriptive statistics, Kaplan-Meier curves, and various tests.
Overall response rate was high at 67% with unconfirmed complete remission in 56% of prior ibrutinib patients.
Median progression-free survival was 46 months; median overall survival not reached, estimated at 52.5 months.
Hematologic adverse events reported in 64% of patients, non-hematologic in 42%, indicating manageable toxicity.

Cite This Study

Chudej et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d218 https://doi.org/10.1182/blood-2025-7424

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark